Raloxifene HCl
Raloxifene HCl structure
|
Common Name | Raloxifene HCl | ||
|---|---|---|---|---|
| CAS Number | 82640-04-8 | Molecular Weight | 510.044 | |
| Density | 1.285g/cm3 | Boiling Point | 728.2ºC at 760 mmHg | |
| Molecular Formula | C28H28ClNO4S | Melting Point | 143-147ºC | |
| MSDS | Chinese USA | Flash Point | 394.2ºC | |
|
Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase.
Drug Metab. Dispos. 42(8) , 1326-33, (2014) Lenvatinib is a multityrosine kinase inhibitor that inhibits vascular endothelial growth factor receptors, and is being developed as an anticancer drug. P450s are involved in one of the elimination pathways of lenvatinib, and mono-oxidized metabolites, such a... |
|
|
Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway.
J. Steroid Biochem. Mol. Biol. 145 , 85-93, (2015) Growing evidence shows that steroid hormones, especially 17β-estradiol (E2), protect neuronal cells by attenuating excess activation of microglia. However, the use of E2 in the clinic is controversial because of its peripheral actions in reproductive organs a... |
|
|
Bioluminescent cell-based NAD(P)/NAD(P)H assays for rapid dinucleotide measurement and inhibitor screening.
Assay Drug Dev. Technol. 12(9-10) , 514-26, (2014) Abstract The central role of nicotinamide adenine dinucleotides in cellular energy metabolism and signaling makes them important nodes that link the metabolic state of cells with energy homeostasis and gene regulation. In this study, we describe the implement... |
|
|
Risk-benefit profiles of women using tamoxifen for chemoprevention.
J. Natl. Cancer Inst. 107(1) , 354, (2015) Tamoxifen has been US Food and Drug Administration-approved for primary prevention of breast cancer since 1998 but has not been widely adopted, in part because of increased risk of serious side effects. Little is known about the risk-benefit profiles of women... |
|
|
Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
Arch. Osteoporos. 9 , 189, (2014) Osteoporosis is a major cause of mortality and morbidity worldwide. Decreased bone turnover markers and increased lumbar spine and total hip bone mineral density (BMD) in raloxifene-treated women add further support to the idea that raloxifene is an effective... |
|
|
[Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].
Nippon. Yakurigaku Zasshi. 125(1) , 37-48, (2005)
|
|
|
[Raloxifene hydrochloride].
Nihon Rinsho. 62 Suppl 2 , 528-35, (2004)
|
|
|
Clinical effects of raloxifene hydrochloride in women.
Ann. Intern. Med. 130(5) , 431-9, (1999) To review clinical data on raloxifene hydrochloride, a selective estrogen receptor modulator that was recently approved for the prevention of osteoporosis in postmenopausal women.English-language articles published from 1980 to May 1998 were identified throug... |
|
|
Use of SERMs for treatment in postmenopausal women
J. Steroid Biochem. Mol. Biol. 142 , 142-54, (2014) • FDA approved selective estrogen receptor modulators (SERMs) prevent and treat breast cancer, osteoporosis and dyspareunia. • SERMs have varying agonist and antagonist activities at the level of the estrogen receptor (ER) in target tissues. • Targeted agonis... |
|
|
Cardiovascular effects of raloxifene hydrochloride.
Cardiovasc. Drug Rev. 19(1) , 57-74, (2001) Raloxifene hydrochloride binds to the estrogen receptor and shows tissue-selective effects; thus, it belongs to a class of drugs recently described as selective estrogen receptor modulators (SERMs). Tissue selectivity of raloxifene may be achieved through sev... |